320 related articles for article (PubMed ID: 15736142)
21. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
Eddama O; Coast J
Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
[TBL] [Abstract][Full Text] [Related]
22. Update on technology assessment in dentistry.
Antczak-Bouckoms A; Tulloch JF
Curr Opin Dent; 1992 Jun; 2():10-4. PubMed ID: 1387819
[TBL] [Abstract][Full Text] [Related]
23. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
Haas M; Hall J; Viney R; Gallego G
Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
[TBL] [Abstract][Full Text] [Related]
24. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
25. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
26. Health technology assessment in the cost-disutility plane.
Eckermann S; Briggs A; Willan AR
Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
[TBL] [Abstract][Full Text] [Related]
27. Measurement of costs.
Riewpaiboon A
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S28-37. PubMed ID: 19253485
[TBL] [Abstract][Full Text] [Related]
28. Making health technology assessment information available for decision making: the development of a Thai database.
Kapol N; Maitreemit P; Chalongsuk R; Amrumpai Y; Sribundit N; Thavorncharoensap M; Chaikledkaew U; Teerawattananon Y
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S8-10. PubMed ID: 19253482
[TBL] [Abstract][Full Text] [Related]
29. Probabilistic analysis and computationally expensive models: Necessary and required?
Griffin S; Claxton K; Hawkins N; Sculpher M
Value Health; 2006; 9(4):244-52. PubMed ID: 16903994
[TBL] [Abstract][Full Text] [Related]
30. Expected value of information and decision making in HTA.
Eckermann S; Willan AR
Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
[TBL] [Abstract][Full Text] [Related]
31. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
Drummond M; Manca A; Sculpher M
Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
[TBL] [Abstract][Full Text] [Related]
32. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
Griffin SC; Weatherly HL; Richardson GA; Drummond MF
Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
[TBL] [Abstract][Full Text] [Related]
33. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
34. The economic valuation of improved process plant decision support technology.
White DC
ISA Trans; 2007 Jun; 46(3):437-42. PubMed ID: 17434170
[TBL] [Abstract][Full Text] [Related]
35. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
36. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
Alshreef A; Jenks M; Green W; Dixon S
Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
[TBL] [Abstract][Full Text] [Related]
37. 10 years of NICE: still growing and still controversial.
Littlejohns P; Garner S; Doyle N; Macbeth F; Barnett D; Longson C
Lancet Oncol; 2009 Apr; 10(4):417-24. PubMed ID: 19341973
[TBL] [Abstract][Full Text] [Related]
38. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
39. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
Maignen F; Osipenko L; Pinilla-Dominguez P; Crowe E
Eur J Clin Pharmacol; 2017 Mar; 73(3):297-305. PubMed ID: 27942759
[TBL] [Abstract][Full Text] [Related]
40. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.
Kaló Z; Landa K; Doležal T; Vokó Z
Eur J Cancer Care (Engl); 2012 Jul; 21(4):442-9. PubMed ID: 22510226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
